Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Indicators

Technical Trend Overview and Price Movement

Anthem Biosciences currently trades at ₹784.00, marginally down from the previous close of ₹784.55. The stock’s 52-week range spans from ₹579.45 to ₹873.25, indicating a significant volatility band. Today’s intraday high and low were ₹790.25 and ₹763.90 respectively, reflecting a relatively tight trading range. The shift from a mildly bullish to a sideways technical trend suggests a consolidation phase, where the stock is pausing after recent gains.

Examining the moving averages on a daily timeframe reveals a neutral stance, with no clear directional bias. This aligns with the sideways trend classification, indicating that short-term momentum is stabilising rather than accelerating.

MACD and RSI Signals: Divergent Weekly and Monthly Perspectives

The Moving Average Convergence Divergence (MACD) indicator on the weekly chart remains bullish, signalling that the medium-term momentum is still positive. This suggests that despite the recent pause, the underlying trend retains upward potential. However, the monthly MACD does not provide a clear signal, reflecting uncertainty over the longer-term momentum.

Relative Strength Index (RSI) readings are similarly inconclusive. The weekly RSI shows no definitive signal, indicating neither overbought nor oversold conditions. The monthly RSI also fails to provide a directional cue, reinforcing the notion of a neutral momentum environment on longer timeframes.

Bollinger Bands and Volume-Based Indicators

Bollinger Bands on the weekly chart remain bullish, with the stock price hovering near the upper band. This typically indicates sustained buying interest and potential for further upside, although the sideways trend tempers expectations of a strong breakout. Conversely, monthly Bollinger Bands do not confirm this bullishness, suggesting that the stock’s longer-term volatility and momentum are less decisive.

Volume-based indicators present a mixed picture. The On-Balance Volume (OBV) on the weekly chart shows no clear trend, implying that volume is not strongly supporting price movements in the short term. More concerning is the monthly OBV, which is bearish, signalling that selling pressure may be increasing over the longer horizon. This divergence between price and volume trends warrants caution for investors relying solely on price momentum.

Dow Theory and KST Indicators: Subtle Signals

According to Dow Theory, the weekly chart shows no clear trend, reinforcing the sideways momentum narrative. The monthly Dow Theory assessment is mildly bullish, indicating that the broader market forces may still favour Anthem Biosciences over the longer term. The Know Sure Thing (KST) indicator data is incomplete for both weekly and monthly periods, limiting the ability to draw firm conclusions from this momentum oscillator.

Comparative Returns: Anthem Biosciences vs Sensex

Anthem Biosciences has outperformed the Sensex significantly over recent periods. The stock delivered a 2.6% return over the past week compared to the Sensex’s decline of 1.62%. Over one month, Anthem gained 5.26% while the Sensex fell by 1.98%. Year-to-date, the stock’s return stands at an impressive 20.42%, contrasting sharply with the Sensex’s negative 10.80%. These figures highlight the stock’s relative strength despite the current technical consolidation.

Longer-term data is unavailable for Anthem Biosciences, but the Sensex’s 3-year, 5-year, and 10-year returns of 22.79%, 54.62%, and 196.97% respectively provide a benchmark for assessing the stock’s potential trajectory once momentum resumes.

Mojo Score and Rating Update

MarketsMOJO has recently downgraded Anthem Biosciences from a Hold to a Sell rating, reflected in a Mojo Score of 40.0 as of 7 May 2026. This downgrade signals a cautious stance based on the company’s current fundamentals and technical outlook. The mid-cap classification further emphasises the stock’s susceptibility to volatility and market sentiment shifts.

Investor Implications and Outlook

The mixed technical signals suggest that investors should approach Anthem Biosciences with prudence. The weekly bullish MACD and Bollinger Bands indicate potential for renewed upward momentum, but the sideways trend and bearish monthly OBV warn of possible resistance or profit-taking ahead. The neutral RSI readings imply that the stock is not currently overextended, leaving room for either a breakout or a deeper consolidation.

Given the recent downgrade and the sideways price action, investors may consider waiting for clearer confirmation of trend direction before initiating new positions. Those holding existing shares should monitor volume trends closely, as a sustained increase in selling pressure could signal a more pronounced correction.

Summary

Anthem Biosciences Ltd’s recent technical parameter changes reflect a transition from mild bullishness to a more cautious sideways trend. Weekly momentum indicators such as MACD and Bollinger Bands remain positive, but monthly volume and trend indicators suggest underlying weakness. The stock’s relative outperformance against the Sensex is a positive backdrop, yet the recent downgrade to a Sell rating by MarketsMOJO underscores the need for vigilance.

Investors should closely monitor the stock’s price action and volume dynamics in the coming weeks to identify a definitive trend. Until then, a conservative approach is advisable, balancing the potential for upside with the risk of consolidation or correction.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →